Physician profile
Mateo Reyes
NPI 1427040427
$1,613.88
in general payments reported to CMS, 2019-2025
25 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $70.12 · 2021: $291 · 2022: $125 · 2023: $88.32 · 2024: $203 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $400.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $416.31 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $219.64 | 2019-2024 | Capvaxive, Gardasil, Vaxneuvance |
| Lilly USA, LLC | $210.54 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $114.23 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.65 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.28 | 2019-2020 | |
| Daiichi Sankyo INC. | $44.92 | 2019-2023 | Injectafer |
| Corium, LLC | $43.46 | 2023-2025 | Azstarys |
| Amarin Pharma, INC. | $40.20 | 2019-2020 | |
| Abbvie INC. | $29.78 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $29.20 | 2019-2024 | Kristalose |
| Phathom Pharmaceuticals, INC. | $28.78 | 2025 | Voquezna |
| Pfizer INC. | $28.03 | 2019 | |
| Radius Health, INC. | $26.55 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.46 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $22.42 | 2021 | |
| Glaxosmithkline, LLC. | $21.58 | 2024 | Bexsero |
| Mission Pharmacal Company | $18.80 | 2019 | |
| Phadia US INC. | $17.28 | 2024 | Immunocap |
| Sanofi-Aventis U.S. LLC | $15.00 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.06 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $13.71 | 2024 | Farxiga |
| Dexcom, INC. | $13.57 | 2022 | |
| Amgen INC. | $12.81 | 2019 | |
| Genentech USA, INC. | $12.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mateo Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.